Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.692,70
0,44%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Arcturus Therapeutics Holdings Inc (ARCT) Arcturus Therapeutics Holdings Inc (ARCT) Notizie

Arcturus Therapeutics Holdings Inc

ARCT
26,55
0,38 (1,45%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202422:01BWArcturus Therapeutics to Report First Quarter Financial..
07/3/202422:05EDGAR2Form 8-K - Current report
07/3/202422:01BWArcturus Therapeutics Announces Fourth Quarter and Fiscal..
26/2/202415:00BWArcturus Therapeutics to Present at the Barclays 26th Annual..
23/2/202422:05EDGAR2Form 8-K - Current report
22/2/202414:30BWArcturus Therapeutics Receives Orphan Medicinal Product..
20/2/202415:00BWArcturus Therapeutics to Report Fourth Quarter and Full Year..
05/2/202414:30PRNUSNew COVID-19 sa-mRNA Results from CSL and Arcturus..
21/12/202314:00PRNUSCSL and Arcturus Therapeutics' ARCT-154 Demonstrates..
20/12/202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202314:30BWArcturus Therapeutics to Present at the 42nd Annual J.P...
28/11/202314:05PRNUSJapan's Ministry of Health, Labour and Welfare Approves CSL..
28/11/202314:00BWJapan's Ministry of Health, Labour and Welfare Approves CSL..
27/11/202315:13DJNArcturus Therapeutics Gets FDA Orphan Designation for..
27/11/202314:30BWArcturus Therapeutics Receives Orphan Drug Designation from..
15/11/202314:51IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Analyst..
14/11/202322:10EDGAR2Form 8-K - Current report
14/11/202322:01BWArcturus Therapeutics Announces Third Quarter 2023 Financial..
25/10/202322:01BWArcturus Therapeutics to Report Third Quarter Financial..
23/10/202322:01BWArcturus Therapeutics to Attend Upcoming Investor &..
04/10/202314:30BWArcturus Therapeutics Joint Venture mRNA Manufacturing..
26/9/202322:06EDGAR2Form 8-K - Current report
26/9/202314:30BWArcturus Therapeutics and Cystic Fibrosis Foundation Extend..
19/9/202314:30BWStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad,..
05/9/202314:30BWArcturus Therapeutics and CSL Announce European Medicines..
17/8/202314:30BWArcturus Therapeutics to Attend Upcoming Investor..
14/8/202315:00BWArcturus Therapeutics Joint Venture mRNA Manufacturing..
07/8/202323:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:23EDGAR2Form 8-K - Current report
07/8/202322:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/8/202322:01BWArcturus Therapeutics Announces Second Quarter 2023..
03/8/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/7/202322:01BWArcturus Therapeutics to Report Second Quarter 2023..
14/7/202313:53EDGAR2Form 8-K - Current report
30/6/202314:28EDGAR2Form 8-K - Current report
01/6/202314:30BWArcturus Therapeutics Receives U.S. FDA Fast Track..
09/5/202322:01BWArcturus Therapeutics Announces First Quarter 2023 Financial..
Apertura: 26,28 Min: 25,84 Max: 26,86
Chiusura: 26,17

La tua Cronologia

NASDAQ
ARCT
Arcturus Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network